{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:57:05Z","timestamp":1792789025362,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Invasive meningococcal disease (IMD) causes high fatality in untreated patients alongside long-term sequelae in 20% survivors. For a comprehensive assessment of epidemiology, an analysis of these sequelae is required. This study aims to investigate the epidemiology of disease between 2008 and 2017 including a description of the sequelae, through the analysis of data collected from the UK Clinical Practice Research Datalink (CPRD) linked with data from the Hospital Episode Statistics (HES), and Office for National Statistics (ONS) mortality registry data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a 10-year retrospective observational cohort study designed to describe the incidence, case-fatality rate (CFR) and occurrence of sequelae due to meningococcal disease, in the UK between 2007 and 2017 using data from the UK CPRD-HES-ONS. Cases were identified and matched on age, gender, date of diagnosis of IMD and followed-up-time with a control group without IMD. Demographics, clinical characteristics, mortality, and IMD-related sequelae were examined for IMD cases and compared with matched controls for a more comprehensive assessment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study analysed 640 IMD patients with majority of the cases diagnosed (76.9%) in a hospital setting. Age-group analysis showed a decrease in the incidence rate of IMD in patients aged &lt;1 year (30.4 \u2013 7.5%) and an increase in those &gt;50 years (10.4 \u2013 27.8%). CFR was slightly higher among females, toddlers, and adults &gt;50 years. No significant change in CFR was observed over study period. Case-control study showed a higher number of IMD sequelae among cases compared to age- and gender-matched controls, especially in those \u2265 50 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study showed that, despite a relatively low incidence rate, IMD is responsible for a high CFR, namely in older age groups and by a high number of IMD sequelae. The study showed that leveraging data from existing databases can be used to complement surveillance data in truly assessing the epidemiology of IMD. Despite the availability of routine vaccination programs, IMD still poses a significant burden in the healthcare system of the UK. Optimization of vaccination programs may be required to reduce the disease burden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-022-12933-3","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T04:38:50Z","timestamp":1647491930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Epidemiology of invasive meningococcal disease and sequelae in the United Kingdom during the period 2008 to 2017 \u2013 a secondary database analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Sandra","family":"Guedes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Bricout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bertrand-Gerentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"12933_CR1","unstructured":"Meningococcal meningitis. February 2018. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningococcal-meningitis\u00a0 Accessed on: 24 Dec\u00a02020."},{"issue":"Suppl 2","key":"12933_CR2","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","volume":"30","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3\u20139.","journal-title":"Vaccine"},{"issue":"4","key":"12933_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","volume":"16","author":"R Borrow","year":"2017","unstructured":"Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313\u201328.","journal-title":"Expert Rev Vaccines"},{"key":"12933_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","volume":"799","author":"NG Rouphael","year":"2012","unstructured":"Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1\u201320.","journal-title":"Methods Mol Biol"},{"issue":"9580","key":"12933_CR5","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","volume":"369","author":"DS Stephens","year":"2007","unstructured":"Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196\u2013210.","journal-title":"Lancet"},{"issue":"3","key":"12933_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/14760584.2018.1432360","volume":"17","author":"A Vyse","year":"2018","unstructured":"Vyse A, Ellsbury G, Madhava H. Protecting UK adolescents and adults against meningococcal serogroup B disease. Expert Rev Vaccines. 2018;17(3):229\u201337.","journal-title":"Expert Rev Vaccines"},{"key":"12933_CR7","unstructured":"Invasive meningococcal disease. Annual Epidemiological Report for 2017. European Center for Disease Control and Prevention. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf Accessed on: 24 Dec\u00a02020."},{"key":"12933_CR8","unstructured":"Enhanced Meningococcal Disease Surveillance Report, 2018. Confirmed and Probable Cases Reported to the National Notifiable Diseases Surveillance System, 2018. CDC. Available from: https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2018.pdf Accessed on: 24 Dec\u00a02020."},{"issue":"4","key":"12933_CR9","first-page":"4","volume":"4","author":"P Gunaratnam","year":"2013","unstructured":"Gunaratnam P, Massey P, Durrheim D, Torvaldsen S. Invasive meningococcal disease in elderly people, New South Wales, Australia, 1993 to 2012. Western Pac Surveill Response J. 2013;4(4):4\u201310.","journal-title":"Western Pac Surveill Response J"},{"key":"12933_CR10","doi-asserted-by":"publisher","first-page":"9287121","DOI":"10.1155\/2019\/9287121","volume":"2019","author":"G Trzewikoswki de Lima","year":"2019","unstructured":"Trzewikoswki de Lima G, De Gaspari E. Study of the Immune Response in the Elderly: Is It Necessary to Develop a Vaccine against Neisseria meningitidis for the Aged? J Aging Res. 2019;2019:9287121.","journal-title":"J Aging Res"},{"issue":"10009","key":"12933_CR11","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/S0140-6736(15)61340-X","volume":"386","author":"GBD DALYs","year":"2015","unstructured":"DALYs GBD, Collaborators H, Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145\u201391.","journal-title":"Lancet"},{"issue":"12","key":"12933_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1474-4422(18)30387-9","volume":"17","author":"GBDM Collaborators","year":"2018","unstructured":"Collaborators GBDM. Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(12):1061\u201382.","journal-title":"Lancet Neurol"},{"issue":"24","key":"12933_CR13","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","volume":"30","author":"SN Ladhani","year":"2012","unstructured":"Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710\u20136.","journal-title":"Vaccine"},{"issue":"12","key":"12933_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1586\/erv.11.159","volume":"10","author":"MA Safadi","year":"2011","unstructured":"Safadi MA, McIntosh ED. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies. Expert Rev Vaccines. 2011;10(12):1717\u201330.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"12933_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/21645515.2015.1108502","volume":"12","author":"P Stefanelli","year":"2016","unstructured":"Stefanelli P, Rezza G. Impact of vaccination on meningococcal epidemiology. Hum Vaccin Immunother. 2016;12(4):1051\u20135.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"12933_CR16","first-page":"e58","volume":"42","author":"M Gobin","year":"2020","unstructured":"Gobin M, Hughes G, Foulkes S, Bagnall H, Trindall A, Decraene V, et al. The epidemiology and management of clusters of invasive meningococcal disease in England, 2010-15. J Public Health (Oxf). 2020;42(1):e58\u201365.","journal-title":"J Public Health (Oxf)"},{"issue":"3","key":"12933_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"},{"key":"12933_CR18","unstructured":"Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2018\/2019. Health Protection Report Volume 13 Number 38. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/842368\/hpr3819_IMD-ann.pdf Accessed on: 28 Dec\u00a02020."},{"issue":"4","key":"12933_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483\u201398.","journal-title":"J Infect"},{"key":"12933_CR20","unstructured":"Public Health England. The Green Book. Chapter 22: Meningococcal. Published Mar 2012. Last updated Sept 2016. Available from: https:\/\/www.gov.uk\/government\/publications\/meningococcal-the-green-book-chapter-22 Accessed on: 28 Dec\u00a02020."},{"issue":"1","key":"12933_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228020","volume":"15","author":"L Huang","year":"2020","unstructured":"Huang L, Heuer OD, Janssen S, Hackl D, Schmedt N. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database. PLoS One. 2020;15(1):e0228020.","journal-title":"PLoS One"},{"key":"12933_CR22","unstructured":"WHO. Defeating meningitis by 2030: a global road map. Available at: https:\/\/www.who.int\/publications\/m\/item\/defeating-meningitis-by-2030-a-global-road-map Accessed on: 31 Jan\u00a02021"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-12933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-12933-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-12933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T04:39:32Z","timestamp":1647491972000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-12933-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["12933"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-12933-3","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Clinical Practice Research Datalink (CPRD) is an ongoing primary care database of anonymised medical records from general practitioners, with coverage of over 11.3 million patients from 674 practices in the UK. All methods were performed in accordance with the relevant guidelines and regulations and the protocol (reference number 18_203) was approved by the UK CPRD Independent Scientific Advisory Committee (ISAC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Sanofi Pasteur and may hold company shares.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"521"}}